loader image
Sunday, December 21, 2025
85.7 F
McAllen
- Advertisement -

Test Early: Save your Life

Translate to Spanish or other 102 languages!

Doctors recommend a screening test to find a disease early, when treatment may work better. Image for illustration purposes
Doctors recommend a screening test to find a disease early, when treatment may work better. Image for illustration purposes

Mega Doctor News

- Advertisement -

Who Should Be Screened for Lung Cancer?

Screening means testing for a disease when there are no symptoms or history of that disease. Doctors recommend a screening test to find a disease early, when treatment may work better.

The only recommended screening test for lung cancer is low-dose computed tomography (also called a low-dose CT scan, or LDCT). During an LDCT scan, you lie on a table and an X-ray machine uses a low dose (amount) of radiation to make detailed images of your lungs. The scan only takes a few minutes and is not painful.

- Advertisement -

Who Should Be Screened?

The U.S. Preventive Services Task Force (USPSTF) recommends yearly lung cancer screening with LDCT for people who—

  • Have a 20 pack-year or more smoking history, and
  • Smoke now or have quit within the past 15 years, and
  • Are between 50 and 80 years old.

pack-year is smoking an average of one pack of cigarettes per day for one year. For example, a person could have a 20 pack-year history by smoking one pack a day for 20 years or two packs a day for 10 years.

Risks of Screening

- Advertisement -

Lung cancer screening has at least three risks—

  • A lung cancer screening test can suggest that a person has lung cancer when no cancer is present. This is called a false-positive result. False-positive results can lead to follow-up tests and surgeries that are not needed and may have more risks.
  • A lung cancer screening test can find cases of cancer that may never have caused a problem for the patient. This is called overdiagnosis. Overdiagnosis can lead to treatment that is not needed.
  • Radiation from repeated LDCT tests can cause cancer in otherwise healthy people.

That is why lung cancer screening is recommended only for adults who are at high risk for developing the disease because of their smoking history and age, and who do not have a health problem that substantially limits their life expectancy or their ability or willingness to have lung surgery, if needed.

If you are thinking about getting screened, talk to your doctor. If lung cancer screening is right for you, your doctor can refer you to a high-quality screening facility.

The best way to reduce your risk of lung cancer is to not smoke and to avoid secondhand smoke. Lung cancer screening is not a substitute for quitting smoking.

When Should Screening Stop?

The Task Force recommends that yearly lung cancer screening stop when the person being screened—

  • Turns 81 years old, or
  • Has not smoked in 15 or more years, or
  • Develops a health problem that makes him or her unwilling or unable to have surgery if lung cancer is found.

Insurance and Medicare Coverage

Most insurance plans and Medicare help pay for recommended lung cancer screening tests. Check with your insurance plan to find out what benefits are covered for lung cancer screening. For more information about Medicare coverage, visit www.medicare.gov or call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1 (877) 486-2048.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 
- Advertisement -
×